ROYALTY PHARMA PLC- CL A (RPRX) 42.24 +0.31 (+0.74%)
42.24 +0.31 (+0.74%)
GB00BMVP7Y09 - Common Stock
Fundamental Rating
We assign a fundamental rating of 5 out of 10 to RPRX. RPRX was compared to 257 industry peers in the Pharmaceuticals industry. RPRX has a medium financial health rating, its profitability is only medium as well. RPRX has a correct valuation and a medium growth rate.
Profitability
Profitability Rating
RPRX's Return On Assets of 2.87% is amongst the best returns of the industry. RPRX outperforms 87% of its industry peers. The industry average Return On Assets is -41.45%.
RPRX's Profit Margin of 22.55% is amongst the best returns of the industry. RPRX outperforms 92% of its industry peers. The industry average Profit Margin is -108.01%.
RPRX has a Piotroski-F score of 4.00. This indicates an average health and profitability for RPRX.
RPRX has a Return On Equity of 8.24%. This is below the industry average of 20.44%.
VS Industry
ROA (2.87%) VS Industry: 87% outperformed.
-1,292.14
111.39
ROE (8.24%) VS Industry: 29% outperformed.
1.38
176.97
Profit Margin (22.55%) VS Industry: 92% outperformed.
-53,337.68
1,968.82
Valuation
Valuation Rating
The Forward Price/Earnings Ratio of 11.91 indicates a rather cheap valuation of RPRX.
RPRX's low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The Price/Earnings Ratio is 14.52, which indicates a correct valuation of RPRX.
RPRX's Price/Earning Ratio is in line with the industry average which is at 14.29.
With a price book ratio of 3.03, RPRX is valued correctly.
When comparing the price book ratio of RPRX to the average industry price book ratio of 1.43, RPRX is valued more expensive than its industry peers.
VS Industry
Price/Earnings (14.52) VS Industry: 44% outperformed.
85.27
0.75
Price/Book (3.03) VS Industry: 29% outperformed.
302.05
0.09
Growth
Growth Rating
RPRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.18%, which is quite impressive.
Based on estimates for the next 5 years, RPRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.15% on average per year.
When comparing the EPS growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
Looking at the last year, RPRX shows a decrease in Revenue. The Revenue has decreased by -1.69% in the last year.
Measured over the past 5 years, RPRX shows a small growth in Revenue. The Revenue has been growing by 8.45% on average per year.
Based on estimates for the next 5 years, RPRX will show a small growth in Revenue. The Revenue will grow by 6.87% on average per year.
The Revenue growth is stable: in the next 5 years the growth will be about the same than in the last 5 years.
RPRX shows a very negative growth in Earnings Per Share. Measured over the last 5 years, the EPS has been decreasing by -13.57% yearly.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | -13.57% | 70.18% | 37.55% | 26.12% | 21.58% | 18.15% |
| Revenue | N/A | 8.45% | -1.69% | 8.62% | 7.42% | 9.6% | 6.87% |
Health
Health Rating
A Current Ratio of 2.07 indicates that RPRX has no problem at all paying its short term obligations.
A Quick Ratio of 2.07 indicates that RPRX has no problem at all paying its short term obligations.
The Altman-Z score of RPRX is much better than the industry average of -0.53.
RPRX has a Piotroski-F score of 4.00. This indicates an average health and profitability for RPRX.
Compared to an average industry Current Ratio of 3.51, RPRX is worse placed to pay its short term obligations than its industry peers.
Compared to an average industry Quick Ratio of 2.88, RPRX is worse placed to pay its short term obligations than its industry peers.
RPRX has one of the worst Debt to Equity ratios in its industry. 88% of its industry peers require less debt for financing their operations.
RPRX has an Altman-Z score of 1.59. This is a bad value and indicates that RPRX is not financially healthy and even has some risk of bankruptcy.
VS Industry
Debt/Equity (0.99) VS Industry: 12% outperformed.
59.36
0.00
Quick Ratio (2.07) VS Industry: 37% outperformed.
-2.73
76.82
Current Ratio (2.07) VS Industry: 28% outperformed.
0.09
76.82
Altman-Z (1.59) VS Industry: 66% outperformed.
-231.44
114.17
Dividend
Dividend Rating
With a Yearly Dividend Yield of 1.77%, RPRX has a reasonable but not impressive dividend return.
RPRX's Dividend Yield is slightly below the industry average, which is at 2.73.
RPRX's Dividend Yield is slightly below the S&P500 average, which is at 2.43.
RPRX pays out 63.68% of its income as dividend. This is not a sustainable payout ratio.
RPRX is new to the dividend game and has less than 3 years of track record.
VS Industry
Dividend Yield (1.77%) VS Industry: 22% outperformed.
0.67
7.18
ROYALTY PHARMA PLC- CL A42.24
NASDAQ:RPRX (12/7/2022, 12:41:06 PM)+0.31 (+0.74%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Pharmaceuticals | ||
| Earnings (Last) | 11-08 2022-11-08/bmo | Earnings (Next) | 02-13 2023-02-13 |
| Ins Owners | 0.1% | Inst Owners | 67.07% |
| Market Cap | 18.63B | Analysts | 81.11 |
| PE | 14.52 | Fwd PE | 11.91 |
| PEG (NY) | 0.39 | PEG (5Y) | N/A |
| P/S | 8.29 | P/B | 3.03 |
| EV/EBITDA | N/A | ||
| Dividend Yield | 1.77% | Dividend Growth | N/A |
| DP | 63.68% | Ex-Date | 11-17 2022-11-17 (0.19) |
| EPS 1Y | 70.18% | EPS 3Y | -13.57% |
| EPS 5Y | N/A | EPS growth Q2Q | 323.53% |
| EPS Next Y | 37.55% | EPS Next 2Y | 26.12% |
| EPS Next 3Y | 21.58% | EPS Next 5Y | 18.15% |
| Revenue growth 1Y | -1.69% | Revenue growth 3Y | 8.45% |
| Revenue growth 5Y | N/A | Revenue growth Q2Q | -2.1% |
| Revenue Next Year | 8.62% | Revenue Next 2Y | 7.42% |
| Revenue Next 3Y | 9.6% | Revenue Next 5Y | 6.87% |
| Current Ratio | 2.07 | Quick Ratio | 2.07 |
| Altman-Z | 1.59 | F-Score | 4 |
| Debt/Equity | 0.99 | WACC | 8.26% |
| ROIC/WACC | 0.63 | ||
| ROA | 2.87% | ROE | 8.24% |
| ROICexgc | 5.2% | ROIC | 4.5% |
| PM | 22.55% | OM | 41.97% |
| Asset Turnover | 0.13 | ||
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA